ArticleCurrent pharmaceutical design2025
Data-independent Acquisition Mass Spectrometry Reveals Exosomal LAMC1 as a Key Determinant of Lung Adenocarcinoma Radiosensitivity, Independent of EGFR Mutation.
Article in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimThis study is formulated to reveal the variables affecting the radio-sensitivity in lung adenocarcinoma (LUAD).
backgroundLUAD patients show varied radiotherapy responses. While epidermal growth factor receptor (EGFR) mutations are often used to predict sensitivity, their reliability is debated, underscoring the need for better biomarkers.
objectiveThe aim of this study was to identify key functional proteins that regulate the sensitivity of LUAD to radiotherapy and to assess the potential value of exosomal LAMC1 as a clinical predictive marker.
methodsIn this study, 103 LUAD patients receiving concurrent radiotherapy were included to assess the relationship between EGFR mutation and survival. Intrinsic radio-sensitivity and different radio-sensitivities in 14 LUAD cell lines with/out EGFR mutation were examined based on the surviving fraction at 2 Gy (SF2). Data-independent acquisition (DIA) and Liquid chromatography-tandem mass spectrometry (LC-MS/MS)- based proteomics were used to investigate the proteomics of the LUAD cell lines. Subsequently, GO/KEGG enrichment analysis was combined with protein-protein interaction (PPI) network screening for key proteins. Nano-flow cytometry was employed to validate changes in radiosensitivity-associated protein expression within exosomes, while siRNA-mediated knockdown was performed to assess the functional impact of specific proteins on LUAD cells.
resultsEGFR mutations were not significantly associated with progression-free survival (PFS)/overall survival (OS). 14 LUAD cell lines displayed intrinsic variations in SF2, and no difference between the EGFR mutation and wild-type groups was reported. 5425 proteins were identified via DIA in 14 LUAD cell lines. After bio-informatics analysis, LAMC1, ITGB4, ITGA6, and CD44 were the most representative core differential proteins for the radio-sensitivity in LUAD cells. Notably, LAMC1 was confirmed as a radiation-resistant protein. Following radiotherapy, LUAD cells secreted exosomes with reduced LAMC1 levels. Moreover, LAMC1 knockdown significantly affected cellular proliferation and apoptosis following the irradiation.
conclusionLAMC1 serves as a critical functional determinant of radiotherapy resistance in LUAD. Its dynamic changes in exosomes demonstrate potential for predicting radiotherapy response, suggesting clinical utility for radiosensitivity assessment and personalized radiotherapy guidance.
Indexed as
Identifiers
40326033What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.